Alzheimer's Patients Treated with INmune Bio's XPro™ Show Reduction in CSF Phospho-Tau and Evidence of RemyelinationGlobeNewsWire • 09/01/21
INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer TrialBenzinga • 08/26/21
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK CellsGlobeNewsWire • 08/25/21
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth ConferenceGlobeNewsWire • 08/10/21
INmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business UpdateGlobeNewsWire • 08/04/21
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4GlobeNewsWire • 07/28/21
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker DataGlobeNewsWire • 07/26/21
INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatmentsPRNewsWire • 07/22/21
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021GlobeNewsWire • 07/19/21
INmune Bio Issues Equity Raise Of $40M At 18% Discount To Fund Alzheimer's Candidate DevelopmentBenzinga • 07/14/21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future DilutionGlobeNewsWire • 06/14/21
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USANGlobeNewsWire • 06/02/21
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021GlobeNewsWire • 05/24/21
INmune Bio, Inc. (INMB) CEO RJ Tesi on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21